Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of MELA Sciences, Inc.(“MELA” or the “Company”) (NASDAQ:MELA - News), concerning whether the company has violated federal securities laws by issuing false and misleading statement to shareholder concerning MELA’s melanoma detection device MelaFind.

The U.S. Food and Drug Administration cast doubt on MelaFind, stating that “[t]he FDA review team has significant concerns this device has not been studied adequately for its current indication for use and therefore puts the health of the public at risk.” In particular, FDA reviewers were concerned about the device’s accuracy rate and have recommended that an additional study be conducted. On this news shares of medical device maker MELA closed down over 54% for the day, to $2.92 per share.

If you are aware of any facts relating to this investigation, or purchased shares of MELA, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email eitan@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate work, private securities offerings, and securities arbitration.

Copyright Business Wire 2010